cmAngio® vs Tempus ECG-AF
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your healthcare facility aims to enhance cardiovascular risk assessment for women during routine mammography screenings. This AI-powered tool leverages existing Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams to detect Breast Arterial Calcifications (BAC) without additional radiation, providing valuable insights for early intervention and improved patient care.
View cmAngio® →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your practice focuses on proactive identification of atrial fibrillation (AF) risk in elderly patients. This AI-based algorithm is specifically designed to analyze 12-lead ECGs from patients aged 65 or older to predict the likelihood of new-onset AF within 12 months, enabling timely follow-up and management for high-risk individuals.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | Tempus ECG-AF |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact vendor |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A, cmAngiou00ae, emphasizes quick installation (less than an hour) and broad compatibility with any DICOM-compliant viewer, suggesting easier integration into existing radiology workflows. Its features like a BAC scorecard and adjustable operating points also contribute to user-friendly interpretation and customization. Tool B, Tempus ECG-AF, specifies compatibility with particular ECG systems, which is less universal.
Clinical Value
TieBoth tools offer significant clinical value by leveraging AI to provide early risk assessments for critical cardiovascular conditions. cmAngiou00ae identifies cardiovascular risk from existing mammograms without additional procedures, while Tempus ECG-AF predicts AF risk in a specific high-risk population from standard ECGs. Both are FDA-cleared and address important gaps in early disease detection.
Pricing & Value
Tempus ECG-AFWhile neither tool offers transparent pricing, Tempus ECG-AF provides a clear financial pathway for adoption by explicitly stating CMS reimbursement codes (CPT 0764T and CPT 0765T) and a Medicare rate of $128.90, effective January 1, 2025. This transparency around reimbursement significantly enhances its value proposition for healthcare providers.
Enterprise Readiness
Tempus ECG-AFBoth tools are FDA-cleared and HIPAA-compliant, essential for enterprise adoption. However, Tempus ECG-AF explicitly confirms the availability of a Business Associate Agreement (BAA), which is a critical component for data privacy and compliance in enterprise healthcare settings.
Innovation
cmAngio®cmAngiou00ae demonstrates a higher degree of innovation by repurposing existing mammography data, traditionally used for breast cancer screening, to identify an entirely different, yet related, health risk: cardiovascular disease. This novel application of AI extracts dual value from a single diagnostic procedure.
Support & Docs
TieNeither the provided structured facts nor web searches yielded specific details regarding the level of support, documentation, or service level agreements for either cmAngiou00ae or Tempus ECG-AF. Therefore, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | Tempus ECG-AF |
|---|---|---|
| Tool Name | cmAngiou00ae | Tempus ECG-AF |
| Primary Function | Detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Input Data Type / Modality | Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | 12-lead ECG recordings |
| Target Patient Population / Use Case | Women undergoing mammograms for insights into cardiovascular health. | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. |
| Compatible Systems | Any DICOM-compliant viewer | FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and Tempus ECG-AF.